Prostate Cancer Metastasis Linked to Revival of Dormant Molecular Program
When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been...Read More
The Prostate Cancer Foundation Collaboration with Pan-Cancer Consortium Clarifies and Promotes Consistent Use of Common Terms for Biomarker and Germline Genetic Testing
LOS ANGELES, Calif., July 7, 2020 — The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish...Read More
New Recommendations Offer Guidance for Clinicians & Patients on Implementing Genetic Testing for Prostate Cancer
PHILADELPHIA — An international panel of experts led by researchers and thought-leaders at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Department of Urology at Jefferson have...Read More
ASCO 2020: Blood Test Predicts Response to Prostate Cancer Treatment
A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track...Read More
Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients...Read More
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy
Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical...Read More
VA Launches Clinical Trial for Veterans with COVID-19 Based on Prostate Cancer Drug
WASHINGTON — Today, the U.S. Department of Veterans Affairs (VA) began a new clinical trial to test a Food and Drug Administration-approved prostate cancer drug as a potential treatment for male...Read More
Major Trial Shows Breast Cancer Drug Can Hit Prostate Cancer Achilles Heel
Olaparib, licensed for breast and ovarian cancer, is effective for some men with prostate cancer too Drug better than targeted hormone therapy in cancers with weaknesses in repairing their DNA...Read More
The Second Annual PCF Black History Month Assist Challenge sets new Fundraising Record by raising more than $500,000 for Prostate Cancer Research
LOS ANGELES, Calif., March 25, 2020 – In its sophomore year, the Second Annual Prostate Cancer Foundation Black History Month Assist Challenge more than tripled its fundraising efforts, compared to...Read More
Molecular Imaging Could Transform Management of People with Aggressive Cancer
VICTORIA, Australia, March 22, 2020: A medical imaging technique known as PSMA PET/CT that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help...Read More